Advancements in Nanomedicine Delivery Systems: Unraveling Immune Regulation Strategies for Tumor Immunotherapy

Overview

Journal Nanomedicine (Lond)

Specialty Biotechnology

Date 2024 Jul 16

PMID 39011582

Authors

Yi Zhang

Xi Chen

Binbin Hu

Bingwen Zou

Yong Xu

Affiliations

Soon will be listed here.

Abstract

This review highlights the significant role of nanodrug delivery systems (NDDS) in enhancing the efficacy of tumor immunotherapy. Focusing on the integration of NDDS with immune regulation strategies, it explores their transformative impacts on the tumor microenvironment and immune response dynamics. Key advancements include the optimization of drug delivery through NDDS, targeting mechanisms like immune checkpoint blockade and modulating the immunosuppressive tumor environment. Despite the progress, challenges such as limited clinical efficacy and complex manufacturing processes persist. The review emphasizes the need for further research to optimize these systems, potentially revolutionizing cancer treatment by improving delivery efficiency, reducing toxicity and overcoming immune resistance.

Citing Articles

Progress in the Application of Molecular Hydrogen in Medical Skin Cosmetology.

Guo N, Zhang Y Clin Cosmet Investig Dermatol. 2025; 18:511-523.

PMID: 40061044 PMC: 11887501. DOI: 10.2147/CCID.S500255.

Emerging Role of Extracellular pH in Tumor Microenvironment as a Therapeutic Target for Cancer Immunotherapy.

Rahman M, Yadab M, Ali M Cells. 2024; 13(22).

PMID: 39594672 PMC: 11592846. DOI: 10.3390/cells13221924.

References

Zhou J, Wang G, Chen Y, Wang H, Hua Y, Cai Z . Immunogenic cell death in cancer therapy: Present and emerging inducers. J Cell Mol Med. 2019; 23(8):4854-4865. PMC: 6653385. DOI: 10.1111/jcmm.14356. View

Song L, Hao Y, Wang C, Han Y, Zhu Y, Feng L . Liposomal oxaliplatin prodrugs loaded with metformin potentiate immunotherapy for colorectal cancer. J Control Release. 2022; 350:922-932. DOI: 10.1016/j.jconrel.2022.09.013. View

Palanivelu L, Liu C, Lin L . Immunogenic cell death: The cornerstone of oncolytic viro-immunotherapy. Front Immunol. 2023; 13:1038226. PMC: 9899992. DOI: 10.3389/fimmu.2022.1038226. View

Galluzzi L, Humeau J, Buque A, Zitvogel L, Kroemer G . Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020; 17(12):725-741. DOI: 10.1038/s41571-020-0413-z. View

Panzarini E, Inguscio V, Fimia G, Dini L . Rose Bengal acetate photodynamic therapy (RBAc-PDT) induces exposure and release of Damage-Associated Molecular Patterns (DAMPs) in human HeLa cells. PLoS One. 2014; 9(8):e105778. PMC: 4139382. DOI: 10.1371/journal.pone.0105778. View

Barber D, Wherry E, Masopust D, Zhu B, Allison J, Sharpe A . Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2005; 439(7077):682-7. DOI: 10.1038/nature04444. View

Huo J, Wang Y, Fu W, Lu N, Liu Z . The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application. Front Immunol. 2022; 13:956090. PMC: 9361790. DOI: 10.3389/fimmu.2022.956090. View

Goldberg M, Maris C, Hipkiss E, Flies A, Zhen L, Tuder R . Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood. 2007; 110(1):186-92. PMC: 1896112. DOI: 10.1182/blood-2006-12-062422. View

Mitchell M, Billingsley M, Haley R, Wechsler M, Peppas N, Langer R . Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2020; 20(2):101-124. PMC: 7717100. DOI: 10.1038/s41573-020-0090-8. View

10.

Emens L, Silverstein S, Khleif S, Marincola F, Galon J . Toward integrative cancer immunotherapy: targeting the tumor microenvironment. J Transl Med. 2012; 10:70. PMC: 3341195. DOI: 10.1186/1479-5876-10-70. View

11.

Hong M, Clubb J, Chen Y . Engineering CAR-T Cells for Next-Generation Cancer Therapy. Cancer Cell. 2020; 38(4):473-488. DOI: 10.1016/j.ccell.2020.07.005. View

12.

Starzer A, Preusser M, Berghoff A . Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle. Ther Adv Med Oncol. 2022; 14:17588359221096219. PMC: 9058458. DOI: 10.1177/17588359221096219. View

13.

Yu M, Yang W, Yue W, Chen Y . Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation. Adv Sci (Weinh). 2022; 9(35):e2204335. PMC: 9762307. DOI: 10.1002/advs.202204335. View

14.

Munn D, Mellor A . The tumor-draining lymph node as an immune-privileged site. Immunol Rev. 2006; 213:146-58. DOI: 10.1111/j.1600-065X.2006.00444.x. View

15.

Yu S, Yi M, Qin S, Wu K . Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. Mol Cancer. 2019; 18(1):125. PMC: 6701025. DOI: 10.1186/s12943-019-1057-4. View

16.

Depil S, Duchateau P, Grupp S, Mufti G, Poirot L . 'Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020; 19(3):185-199. DOI: 10.1038/s41573-019-0051-2. View

17.

Li Q, Shi Z, Zhang F, Zeng W, Zhu D, Mei L . Symphony of nanomaterials and immunotherapy based on the cancer-immunity cycle. Acta Pharm Sin B. 2022; 12(1):107-134. PMC: 8799879. DOI: 10.1016/j.apsb.2021.05.031. View

18.

Gu Z, Wang Q, Shi Y, Huang Y, Zhang J, Zhang X . Nanotechnology-mediated immunochemotherapy combined with docetaxel and PD-L1 antibody increase therapeutic effects and decrease systemic toxicity. J Control Release. 2018; 286:369-380. DOI: 10.1016/j.jconrel.2018.08.011. View

19.

Ladoire S, Hannani D, Vetizou M, Locher C, Aymeric L, Apetoh L . Cell-death-associated molecular patterns as determinants of cancer immunogenicity. Antioxid Redox Signal. 2013; 20(7):1098-116. DOI: 10.1089/ars.2012.5133. View

20.

Blank C, Brown I, Peterson A, Spiotto M, Iwai Y, Honjo T . PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2004; 64(3):1140-5. DOI: 10.1158/0008-5472.can-03-3259. View